A novel role for keratin 17 in coordinating oncogenic transformation and cewllular adhesion in ewing sarcoma

Molecular and Cellular Biology

Volumn 33, Issue 22, 2013, Pages 4448-4460

  Sankar, Savita ^a   Tanner, Jason M ^a   Bell, Russell ^b   Chaturvedi, Aashi ^a   Randall, R Lor ^a,b   Beckerle, Mary C ^a,c   Lessnick, Stephen L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 17; PROTEIN KINASE B; TRANSCRIPTION FACTOR GLI1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL ADHESION; CELL CYCLE REGULATION; CONTROLLED STUDY; EWING SARCOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-17; MICE; MICE, NUDE; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS C-AKT; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84886998616     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00241-13     Document Type: Article

References (67)

1. Arndt CA, Crist WM. 1999. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 341:342-352.
2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162-165.
3. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL. 2006. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 9:405-416.
4. Kinsey M, Smith R, Lessnick SL. 2006. NR0B1 is required for the onco-genic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol. Cancer Res. 4:851-859.
5. Prieur A, Tirode F, Cohen P, Delattre O. 2004. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein Mol. Cell. Biol. 24:7275-7283.
6. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M. 2012. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res. 18:748-757.
7. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M. 2005. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J. Clin. Oncol. 23:548-558.
8. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, Denny CT. 1993. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13:7393-7398.
9. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G, Denny CT. 1993. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNAbinding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. U. S. A. 90:5752-5756.
10. Owen LA, Kowalewski AA, Lessnick SL. 2008. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS One 3:e1965. 10.1371/journal.pone.0001965.
11. Kasper M, Regl G, Frischauf AM, Aberger F. 2006. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur. J. Cancer 42: 437-445.
12. Ingham PW, Mcmahon AP. 2001. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15:3059-3087.
13. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sorensen N, Berthold F, Henk B, Schmandt N, Wolf HK, von Deimling A, Wainwright B, Chenevix-Trench G, Wiestler OD, Wicking C. 1997. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 57:2085-2088.
14. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgard R, Unden AB. 2006. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J. Pathol. 208:17-25.
15. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, Wainwright B, Bale AE. 1996. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85:841-851.
16. Sheng T, Li C, Zhang X, Chi S, He N, Chen K, Mccormick F, Gatalicaz, Xie J. 2004. Activation of the hedgehog pathway in advanced prostatecancer. Mol. Cancer 3:29. doi:10.1186/1476-4598-3-29.
17. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, Mcmahon M, Warshaw AL, Hebrok M. 2003. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856.
18. Bian YH, Huang SH, Yang L, Ma XL, Xie JW, Zhang HW. 2007. Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J. Gastroenterol. 13:1659-1665.
19. Chi S, Huang S, Li C, Zhang X, He N, Bhutani MS, Jones D, Castro CY, Logrono R, Haque A, Zwischenberger J, Tyring SK, Zhang H, Xie J. 2006. Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett. 244:53-60.
20. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. 2003. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846-851.
21. Ruiz i Altaba A, Sanchez P, Dahmane N. 2002. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer 2:361-372.
22. Riobo NA, Lu K, Emerson CP, Jr. 2006. Hedgehog signal transduction: signal integration and cross talk in development and cancer. Cell Cycle 5:1612-1615.
23. Sankar S, Bell R, Patel M, Davis IJ, Lessnick SL, Luo W. 17 May 2013. EWS and RE1-silencing transcription factor inhibit neuronal phenotype development and oncogenic transformation in Ewing sarcoma. Genes Cancer [Epub ahead of print.] doi:10.1177/1947601913489569
24. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y, Rubin JS, Toretsky J, Uren A. 2009. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J. Biol. Chem. 284:9074-9082.
25. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA. 2008. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 27:3282-3291.
26. Joo J., Christensen L., Warner K., States L., Kang H.G., Vo K., Lawlor E.R., May W.A. GLI1 IS A CENTRAL MEDIATOR OF EWS/FLI1 SIGNALING IN EWING TUMORS 2009 PLoS One 4:e7608. doi:10.1371/journal.pone.0007608
27. Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL. 2006. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle 5:2753-2759.
28. Zhang J, Lodish HF. 2004. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors. Blood 104:1679-1687.
29. Lessnick SL, Dacwag CS, Golub TR. 2002. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1:393-401.
30. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL. 2012. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.Oncogene [Epub ahead of print.] 26 November doi:10.1038/onc.2012.525.
31. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL. 2008. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc. Natl. Acad. Sci. U. S. A. 105:10149-10154.
32. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. 2007. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. 21:1882-1894.
33. Oler AJ, Alla RK, Roberts DN, Wong A, Hollenhorst PC, Chandler KJ, Cassiday PA, Nelson CA, Hagedorn CH, Graves BJ, Cairns BR. 2010. Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors. Nat. Struct. Mol. Biol. 17:620-628.
34. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC. 2012. The EWS/FLI oncogene drives changes in cellular morphology, adhesion, and migration in Ewing sarcoma. Genes Cancer 3:102-116.
35. Hui CC, Angers S. 2011. Gli proteins in development and disease. Annu. Rev. Cell Dev. Biol. 27:513-537.
36. Yoon JW, Kita Y, Frank DJ, Majewski RR, Konicek BA, Nobrega MA, Jacob H, Walterhouse D, Iannaccone P. 2002. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J. Biol. Chem. 277:5548-5555.
37. Cavazzana AO, Miser JS, Jefferson J, Triche TJ. 1987. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am. J. Pathol. 127:507-518.
38. Lipinski M, Hirsch MR, Deagostini-Bazin H, Yamada O, Tursz T, Goridis C. 1987. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int. J. Cancer 40:81-86.
39. Hallikas O, Palin K, Sinjushina N, Rautiainen R, Partanen J, Ukkonen E, Taipale J. 2006. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. Cell 124:47-59.
40. winklmayr M, Schmid C, Laner-Plamberger S, Kaser A, Aberger F,Eichberger T, Frischauf AM. 2010. Non-consensus GLI binding sites in Hedgehog target gene regulation. BMC Mol. Biol. 11:2. doi:10.1186/1471-2199-11-2.
41. Grant CE, Bailey TL, Noble WS. 2011. FIMO: scanning for occurrences of a given motif. Bioinformatics 27:1017-1018.
42. Ohali A, Avigad S, Zaizov R, Ophir R, Horn-Saban S, Cohen IJ, Meller I, Kollender Y, Issakov J, Yaniv I. 2004. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 23:8997-9006.
43. Coulombe PA, Tong X, Mazzalupo S, Wang Z, Wong P. 2004. Great promises yet to be fulfilled: defining keratin intermediate filament function in vivo. Eur. J. Cell Biol. 83:735-746.
44. Depianto D, Kerns ML, Dlugosz AA, Coulombe PA. 2010. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat. Genet. 42:910-914.
45. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduch M, Murray P, Kolar Z. 2007. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7:55. doi:10.1186/1471-2407-7-55.
46. Smedts F, Ramaekers F, Troyanovsky S, Pruszczynski M, Link M, Lane B, Leigh I, Schijf C, Vooijs P. 1992. Keratin expression in cervical cancer. Am. J. Pathol. 141:497-511.
47. Bournet B, Pointreau A, Souque A, Oumouhou N, Muscari F, Lepage B, Senesse P, Barthet M, Lesavre N, Hammel P, Levy P, Ruszniewski P, Cordelier P, Buscail L. 2012. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Pancreatology 12:27-34.
48. Zhang J, Wang K, Liu SS, Dai L, Zhang JY. 2011. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J. Proteome Res. 10:2863-2872.
49. Shi I, Hashemi Sadraei N, Duan ZH, Shi T. 2011. Aberrant signaling pathways in squamous cell lung carcinoma. Cancer Inform. 10:273-285.
50. Ossandon FJ, Villarroel C, Aguayo F, Santibanez E, Oue N, Yasui W,Corvalan AH. 2008. In silico analysis of gastric carcinoma. Serial analysis of gene expression libraries reveals different profiles associated with ethnicity. Mol. Cancer 7:22. doi:10.1186/1476-4598-7-22.
51. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P. 2002. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 161:1991-1996.
52. Ide M, Kato T, Ogata K, Mochiki E, Kuwano H, Oyama T. 2012. Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann. Surg. Oncol. 19:3506-3514.
53. Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K. 2007. Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am. J. Clin. Pathol. 128:255-259.
54. Kim S, Wong P, Coulombe PA. 2006. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 441:362- 365.
55. Pan X, Kane LA, Van Eyk JE, Coulombe PA. 2011. Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion. J. Biol. Chem. 286: 42403-42413.
56. Altomare DA, Testa JR. 2005. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455-7464.
57. Okegawa T, Pong RC, Li Y, Hsieh JT. 2004. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim. Pol. 51:445-457.
58. Dahlin DC, Coventry MB, Scanlon PW. 1961. Ewing's sarcoma. A critical analysis of 165 cases. J. Bone Joint Surg. Am. 43-A:185-192.
59. Wang CC, Schulz MD. 1953. Ewing's sarcoma; a study of fifty cases treated at the Massachusetts General Hospital, 1930-1952 inclusive. N. Engl. J. Med. 248:571-576.
60. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E. 2010. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr. Blood Cancer 54:13-18.
61. Wang S, Basson MD. 2011. Protein kinase B/AKT and focal adhesion kinase: two close signaling partners in cancer. Anticancer Agents Med. Chem. 11:993-1002.
62. Irby RB, Yeatman TJ. 2000. Role of Src expression and activation in human cancer. Oncogene 19:5636-5642.
63. Yeatman TJ. 2004. A renaissance for SRC. Nat. Rev. Cancer 4:470-480.
64. Huveneers S, Arslan S, van de Water B, Sonnenberg A, Danen EH. 2008. Integrins uncouple Src-induced morphological and oncogenic transformation. J. Biol. Chem. 283:13243-13251.
65. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P. 2010. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 11:129-135.
66. Kelleher F.C., Thomas D.M. 2012, Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours 2 Clin. Sarcoma Res 6. doi:10.1186/2045-3329-2-6.S
67. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M, Picci P, Scotlandi K. 2004. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. Int. J. Cancer 108:358-366.